Veracyte Inc (VCYT) Releases Earnings Results, Misses Expectations By $-0.01 EPS

Veracyte Inc (VCYT) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.36 earnings per share for the quarter, missing the analyst consensus estimate by $-0.01. Analysts had a consensus of $-0.35. The company posted revenue of $13.55 million in the period, compared to analysts expectations of $13.06 million. The company’s revenue was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.34 EPS.

Veracyte Inc closed down -0.31 points or -5.54% at $5.29 with 62,914 shares getting traded on Wednesday. Post opening the session at $5.59, the shares hit an intraday low of $5.26 and an intraday high of $5.79 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Nov 25, 2015, Evan/ Fa Jones (director) sold 15,000 shares at $7.22 per share price. According to the SEC, on Jul 28, 2015, Shelly D Guyer (Chief Financial Officer) sold 1,000 shares at $12.47 per share price. On Jul 23, 2015, Christopher M Hall (Chief Operating Officer) sold 2,500 shares at $11.85 per share price, according to the Form-4 filing with the securities and exchange commission.

Veracyte Inc. is a molecular diagnostics company. The Company is engaged in the field of molecular cytology providing genomic solutions to resolve diagnostic ambiguity and enable physicians to make treatment decisions at an early stage in patient care. It targets diseases in which a large number of patients undergo invasive diagnostic procedures that could be avoided with a diagnosis from a cytology sample. The Company’s commercial solution the Afirma Thyroid FNA Analysis includes as its centerpiece the Gene Expression Classifier (GEC). The GEC allows physicians reduce the number of surgeries by employing a 142-gene signature to pre-operatively determine whether thyroid nodules previously classified by cytopathology as indeterminate can be reclassified as benign. The offering also includes cytopathology testing and the Afirma Malignancy Classifiers. The Company markets and sells Afrma through a co-promotion agreement with Genzyme Corporation a subsidiary of Sanofi.

Veracyte Inc

Leave a Reply

Veracyte Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Veracyte Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.